<sup>18</sup>F-FPPRGD2 and <sup>18</sup>F-FDG PET of Response to Abraxane Therapy

Sun, Xilin; Yan, Yongjun; Liu, Shuanglong; Cao, Qizhen; Yang, Min; Neamati, Nouri; Shen, Baogen; Niu, Gang; Chen, Xiaoyuan

doi:10.2967/jnumed.110.080606

Cited by 53 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 On the other hand, the tumor vasculature endothelial cells are of mouse origin and the CNE-2 tumor cells are of human origin in NPC xenograft model. 28 Furthermore, most of β3 was found to bind to av (avβ3) or aIIb (aIIbβ3), but in tumors the latter is hardly expressed. Hence, only immunofluorescence with anti-murine integrin β3 antibody was performed to confirm the integrin avβ3 expression in CNE-2 tumor tissue.…”

Section: Evaluation Of Integrin Avβ3 Binding In Vivomentioning

confidence: 99%

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

Cui¹,

Zhang²,

Luo³

et al. 2016

IJN

View full text Add to dashboard Cite

Section: Evaluation Of Integrin Avβ3 Binding In Vivomentioning

confidence: 99%

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

Cui¹,

Zhang²,

Luo³

et al. 2016

IJN

View full text Add to dashboard Cite

“…Intensive 18 F-FDG uptake in the myocardium is due to the high metabolic rate (27). Thus, 18 F-FDG PET provides an anatomic reference to the site of infarction and reflects the reduced metabolism of the infarcted area.…”

Section: Image Colocalizationmentioning

confidence: 99%

PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury

et al. 2012

Self Cite

View full text Add to dashboard Cite

Glucagonlike peptide (GLP-1) and its receptor (GLP-1R) exhibit cardioprotective effects after myocardial ischemia and reperfusion (MI/R) in both animal studies and clinical trials. However, the kinetics of GLP-1R expression in the infarcted/ischemic myocardium has not yet been explored. The purpose of this study was to monitor the presence and time course of regional myocardial GLP-1R expression after MI/R with noninvasive PET. Methods: Male Sprague-Dawley rats underwent a 45-min transient left coronary artery occlusion, followed by reperfusion. The myocardial infarction was confirmed by electrocardiogram and cardiac ultrasound. In vivo PET was performed to determine myocardial uptake of 18 F-FBEM-Cys 40 -exendin-4 at different time points after reperfusion. The localization of 18 F-FBEM-Cys 40 -exendin-4 accumulation was determined by coregistering 18 F-FDG PET and CT images. Ex vivo autoradiography, GLP-1R immunohistochemical staining, and Western blot analysis were performed to confirm the PET results. Results: Myocardial origin and infarcted/ischemic area localization of 18 F-FBEM-Cys 40 -exendin-4 accumulation was confirmed by coregistration of small-animal CT and 18 F-FDG images. At 8 h after MI/R, tracer uptake in the infarcted/ischemic region was 0.37 6 0.05 percentage injected dose per gram, significantly higher than that in the control group (P , 0.01). The localized tracer uptake decreased, relative to the 8-h time point, but was still significantly higher than the control group on days 1 and 3 after MI/R. At 2 wk after MI/R, the tracer uptake in the affected area showed no significant difference, compared with that in the healthy myocardium. Autoradiography showed the same trend of 18 F-FBEM-Cys 40 -exendin-4 uptake in the myocardial infarcted/ischemic area. The specificity of tracer uptake into ischemic myocardium was supported by decreased tracer uptake after the rats were pretreated with an excess amount of unlabeled exendin-4. Immunohistochemical staining and Western blotting of GLP-1R protein of excised cardiac sections confirmed that the change in uptake observed by PET corresponded to a change in GLP-1R expression. Conclusion: Noninvasive PET using 18 F-FBEM-Cys 40 -exendin-4 revealed a dynamic pattern of GLP-1R upregulation in the infarcted/ischemic area after MI/R. The imaging results will deepen our understanding of the mechanism of the cardioprotective effect of GLP-1 and its analogs and potentially provide guidance for optimization of the time frame of therapeutic intervention.

show abstract

“…In contrast to optical imaging, PET and SPECT are highly sensitive and quantitative and can detect the therapeutic response earlier than anatomic imaging techniques such as CT. Previous studies (20,21) have demonstrated that 18 F-FDG imaging has limitations or is not optimal for monitoring therapeutic tumor response, with one of the major reasons for this finding being that 18 F-FDG is not tumor-specific, as it also shows high uptake in benign conditions such as inflammation. Many solid tumors are perfused with inflammatory cells (22,23), and thus monitoring tumor therapy using 18 F-FDG may be confused by treatment-induced inflammatory changes (20,21).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies (20,21) have demonstrated that 18 F-FDG imaging has limitations or is not optimal for monitoring therapeutic tumor response, with one of the major reasons for this finding being that 18 F-FDG is not tumor-specific, as it also shows high uptake in benign conditions such as inflammation. Many solid tumors are perfused with inflammatory cells (22,23), and thus monitoring tumor therapy using 18 F-FDG may be confused by treatment-induced inflammatory changes (20,21). A previous study demonstrated that dasatinib could inhibit the production of proinflammatory cytokines in vitro (24).…”

Section: Discussionmentioning

confidence: 99%

Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy

et al. 2015

View full text Add to dashboard Cite

Noninvasive, real-time, quantitative measurement of key biomarkers associated with cancer therapeutic interventions could provide a better understanding of cancer biology. We investigated in this study whether incorporating multiple molecular imaging approaches could be used to guide dasatinib anti-Src therapy and aid in the rational design of a combination therapy regimen. Methods: Bioluminescence imaging, 18 F-FDG PET, integrin α v β 3 -targeted SPECT/ CT, and vascular endothelial growth factor-targeted near-infrared fluorescence imaging were performed before and after dasatinib treatment in a tumor mouse model. Results: There was no significant difference in the bioluminescence imaging signal or 18 F-FDG tumor uptake in dasatinib-treated tumors compared with the control tumors. However, the uptake of 99m T-3PRGD2 (integrin α v β 3 -specific) and DyLight755-ranibizumab (vascular endothelial growth factor-specific) in the dasatinib-treated tumors was significantly lower than that in the control tumors. In vitro studies confirmed the antiangiogenic effects of dasatinib but indicated a lack of cytotoxicity. Dasatinib plus cytotoxic docetaxel elicited marked synergistic tumor growth inhibition in vivo. Conclusion: Visualization of post-Src inhibition tumor signatures through multiple imaging approaches facilitates sensitive and quantitative measurement of cancer biomarkers in vivo, thus aiding in the rational design of dasatinib combination therapy.

show abstract

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

Cited by 53 publications

References 34 publications

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury

Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy

Contact Info

Product

Resources

About

18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy

Cited by 53 publications

References 34 publications

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles

PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury

Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy

Contact Info

Product

Resources

About

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy